CBS NewsFacebook's IPO price was right (maybe)CBS NewsThe average analyst target for Facebook's stock price is just under $38, or right about what the IPO price was.Tech IPOs look to break Facebook curseMarketWatchFacebook stock edges lower as …
Extended excerpt from the Executive Summary. The Treasury had a very light calendar and easy skating last week, but the calendar will be heavier in…
The question is, from where? Facebook is Top Short-Seller Target Among Large Stocks – Bloomberg No large U.S. company is attracting more attention from short…
Facebook Is Biggest Short-Seller Target Among Large U.S. StocksSan Francisco ChronicleFacebook, which has a market value of about $61.6 billion, isn't in the S&P 500. Shares of Facebook have slumped 32 percent since they began trading on May 18…
Facebook is Top Short-Seller Target Among Large StocksBloombergFacebook, which has a market value of about $61.6 billion, isn't in the S&P 500. Shares of Facebook have slumped 32 percent since they began trading on May 18 amid concern that the …
US House Republicans target funding for CFTCReuters* House GOP seek to slash CFTC 2013 budget by $25 mln * Propose modest increase for SEC of $50 mln * Democrats: JPMorgan loss is a case for funding boost * Appropriations panels to review budgets Wedne…
Wall Street JournalJP Morgan Is Target of Japan Insider ProbeWall Street JournalWhile Japan is a relatively minor market for the Wall Street firm, the development is another potential embarrassment as JP Morgan still reels from the fallout of a $2-bill…
Financial NewsJP Morgan Shares Now Negative for Year as Analysts Add CutsWall Street Journal (blog)According to FactSet Research, nearly three-quarters of the 37 analysts on JP Morgan rate it a buy or the equivalent of buy. Evercore — Downgrade to eq…
Yesterday was another victory for bears, and the market is now in a price zone that crosses numerous long-term support levels. It’s also sufficiently oversold that it’s advisable to watch for a potential bounce.&nbs…
New York TimesGlaxoSmithKline target adopts 'poison pill'Philadelphia InquirerBy David Sell Human Genome Sciences Inc. filed a plan with regulators Thursday to try to block GlaxoSmithKline PLC's $2.6 billion takeover offer for the Maryland-…
